Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4418959 first-in-human study in dMMR/MSI-H solid tumors
NL-OMON59362Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GSK4418959 in Nonhematologic neoplasms, colorectal cancer (CRC) and endometrial cancer (EC) (4 arms), sponsored by GSK. Primary endpoints: Incidence of dose-limiting toxicities, Incidence of treatment-emergent adverse events in DLT period and 2 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
GSK4418959
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON59362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59362.